(Q35650530)

English

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors

scientific article published on September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

based on heuristic

inferred from title

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

Françoise Kraeber-Bodéré

4

object named as

Françoise Kraeber-Bodéré

0 references

Alain Faivre-Chauvet

8

object named as

Alain Faivre-Chauvet

0 references

Catherine Saï-Maurel

7

object named as

Catherine Saï-Maurel

0 references

Joëlle Gaschet

11

object named as

Joëlle Gaschet

0 references

Delphine Loussouarn

6

object named as

Delphine Loussouarn

0 references

object named as

Jacques Barbet

10

0 references

author name string

Caroline Rousseau

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Anne Lise Ruellan

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Karine Bernardeau

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sebastien Gouard

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

John Wijdenes

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Michel Chérel

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

François Davodeau

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

1 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

EJNMMI Research

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Management of triple negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

What is triple-negative breast cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Prognostic markers in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Therapeutic value of glycosaminoglycans in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Functions of cell surface heparan sulfate proteoglycans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

12 July 2018

Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

Prognostic value of syndecan-1 expression in breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

25 September 2018

Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250983

25 September 2018

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1186%2F2191-219X-1-20

21 January 2018

Transient expression of a cell surface heparan sulfate proteoglycan (syndecan) during limb development

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22214534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/2191-219X-1-20

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35650530&oldid=2197578582"